CANNAINVESTOR Magazine U.S. Publicly Traded April 2018 | Page 73
Our Products
Launched in late spring 2017, Evolve
Formulas’ game-changing transdermal
product NanoSerum™, enables cannabis to
be rapidly absorbed into systemic circulation
for direct-focus relief from pain, inflammation
and anxiety. NanoSphere will offer two more
product applications under the brand name
Evolve: an intra-nasal delivery and an
intra-oral delivery. Each application will be
offered in varying strengths and strains.
CSE: NSHS
Strong Top-Line Growth
Sustainable top-line revenue growth leading
technology
Diversified growing platforms
Targeted geographic expansion
Shares Issued
96.1M 9.8M
Fully Diluted Market Cap
105.9M
Investment
Highlights
Warrants/Options
$79M
Management
Robert Sutton , Chairman and CEO
Operational
Excellence
Robust pipeline of new
and innovative products
Rapid, scalable,
cost-efficient and
proprietary
manufacturing
process
First & ONLY pharma-
ceutical delivery system
for commercial products
Solid and expanding
IP portfolio
Share Structure
As of Dec. 5, 2017
Disruptive
Technology
Unparalleled IP that can be
leveraged and licensed
throughout the world across
multiple industry channels
Ongoing & comprehensive
clinical trials and testing
protocols
Category Leadership
First and only commercial
nanotechnology platform
Innovation driven to address
unmet needs
Award-winning product in
cannabis industry
David Sutton , President and COO
Richard Clark Kaufman PhD, Chief Science Officer
Terry Grossman , Chief Medical Officer
Victor Gonclaves , Executive Vice President
Bennett Liu , CFO
Contact
US Corporate Contact
600 - 8400 E. Crescent Parkway
Greenwood Village, CO 80111
www.nanospherehealth.com
720.528.4437
[email protected]
Canada Contact
488 - 1090 West Georgia Street
Vancouver, British Columbia
Victor Goncalves
204-997-5517
[email protected]